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Abstract
Background: Idiopathic pulmonary fibrosis exhibits differential progression from the time of diagnosis but the molecular
basis for varying progression rates is poorly understood. The aim of the present study was to ascertain whether differential
miRNA expression might provide one explanation for rapidly versus slowly progressing forms of IPF.
Methodology and Principal Findings: miRNA and mRNA were isolated from surgical lung biopsies from IPF patients with a
clinically documented rapid or slow course of disease over the first year after diagnosis. A quantitative PCR miRNA array
containing 88 of the most abundant miRNA in the human genome was used to profile lung biopsies from 9 patients with
rapidly progressing IPF, 6 patients with slowly progressing IPF, and 10 normal lung biopsies. Using this approach, 11 miRNA
were significantly increased and 36 were significantly decreased in rapid biopsies compared with normal biopsies. Slowly
progressive biopsies exhibited 4 significantly increased miRNA and 36 significantly decreased miRNA compared with normal
lung. Among the miRNA present in IPF with validated mRNA targets were those with regulatory effects on epithelial-
mesenchymal transition (EMT). Five miRNA (miR-302c, miR-423-5p, miR-210, miR-376c, and miR-185) were significantly
increased in rapid compared with slow IPF lung biopsies. Additional analyses of rapid biopsies and fibroblasts grown from
the same biopsies revealed that the expression of AGO1 and AGO2 (essential components of the miRNA processing RISC
complex) were lower compared with either slow or normal lung biopsies and fibroblasts.
Conclusion: These findings suggest that the development and/or clinical progression of IPF might be the consequence of
aberrant miRNA processing.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproli-
ferative disorder characterized by excessive, irreversible scarring of
the lungs [1]. The incidence and prevalence of IPF have both
steadily increased over the past two decades [2], and this disease
presently claims more lives annually in the United States than
many types of cancer [3]. From the time of a definitive diagnosis of
IPF, patient prognosis is grim since their median survival time is
approximately 2.8 years [4]. IPF is characterized by pronounced
collagen deposition and other alterations to the extracellular
matrix, which dramatically remodels and stiffens the lung’s distal
airspaces and parenchyma [3]. Difficulty breathing and eventual
death are caused by incurrent pneumonia or respiratory failure.
Currently, pharmacologic treatments for IPF are ineffective at
halting the IPF progression and treatment options aside from lung
transplantation are the focus of active investigation [5]. There is
presently no consensus on the etiopathogeneis of IPF, but various
genetic and environmental factors have been implicated [3].
Although a high degree of variability in IPF progression has
been observed in patients [6–9], the identification of key indicators
that predict disease progression has been elusive. Some have
proposed that high-resolution computed tomography can be
employed to identify IPF patients at greater risk of earlier death
[10], but this diagnostic approach has recently been challenged as
being unreliable [11]. Molecular analysis of lung tissue resected for
diagnostic purposes have provided more encouraging results
suggesting that IPF lung biopsies have a unique messenger RNA
transcriptome compared with non-fibrotic or normal control
biopsy samples [12,13]. This molecular approach has been
extended toward defining biologically relevant transcript differ-
ences in IPF patients with differing disease progression [7,8,14–
17]. Thus, previous studies have highlighted that the analysis of
molecular transcripts from IPF patients might aid in enhancing
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21253our understanding of the biological processes driving lung fibrosis,
which in turn might aid in the identification of patients at greatest
risk for rapid progression.
There is growing evidence that the regulation of gene
transcription in health and disease involves several non-redundant
mechanisms. One such mechanism involves microRNA, which are
22 nucleotide non-coding RNA molecules that exert a biologically
important effect on post-transcriptional gene expression [18]. Each
miRNA is predicted to target hundreds of mRNA transcripts [19]
and approximately one-third of human genes are targeted or
regulated via miRNA-dependent processes [20]. MiRNA biosyn-
thesis in the cell nucleus is regulated by RNase III Drosha [21] and
Exportin 5 [22]. In the cytoplasm, Dicer1 is required for further
processing [21,23] before the miRNA duplex is loaded into the
RNA induced silencing complex (RISC) [18,24]. The RISC is
made up of many proteins of which the Argonaute (AGO) proteins
are the core catalytically active subunits [25,26]. This large
ribonucleoprotein complex uses base pairing interactions with the
miRNA’s 7 nucleotide long ‘‘seed region’’ to target the 39UTR of
different mRNA transcripts which inhibits their translation or
causes their degradation [27]. The degradation of mRNA levels
through destabilization accounts for the majority ($84%) of the
decreased protein output, so changes in mRNA levels can be used
to estimate changes in protein production [28].
MicroRNAs have been implicated in cancer, heart and
neurodegenerative diseases, diabetes, and inflammation [29].
Furthermore, miRNA have also been involved in many forms of
tissue fibrosis [30]. For example, differences in miR-21, miR-29,
miR-30, and miR-133 expression have been examined in cardiac
fibrosis[31–33].AconnectionbetweenmiRNAand fibrosishasalso
been shown in diabetic kidney sclerosis [34], liver fibrosis [35,36],
cysticfibrosis[37],anddiabeticneuropathy[38].More recently,the
downregulationof let-7d [39], upregulationof miR-21[40], and the
downregulation of miR-29 [41] were shown to contribute to the
enhanced fibrosis observed in IPF. However, it remains to be
determined whether differential miRNA expression contributes to
variations in the clinical progression of pulmonary fibrosis.
The aim of the present study was two fold: 1) to determine
whether miRNA biosynthesis differed between IPF and normal
lung tissues; and 2) to determine whether miRNA expression
differed between IPF patients exhibiting varying speeds of disease
progression. Herein, we report that the miRNA levels in diagnostic
lung biopsies markedly differ in both rapidly progressive and
slowly progressive IPF patients compared with normal individuals,
albeit the large majority of the miRNA identified were significantly
lower in the IPF biopsies compared with the normal biopsies.
Among the miRNA present in IPF with validated mRNA targets
were those with regulatory effects on epithelial-mesenchymal
transition (EMT), a process of emerging importance in IPF [42]. A
low-density mRNA array profile of the three biopsy groups
revealed that the rapid IPF group had marked increases in several
mesenchymal markers compared with the slow IPF and normal
groups supporting. A comparison of biopsies from rapidly
progressive patients with biopsies from slowly progressive patients
revealed 5 miRNA that were significantly higher in the first group,
suggesting that the miRNA profile in lung biopsy tissue might be
useful in distinguishing rapidly from slowly progressing IPF.
Finally, both AGO1 and AGO2 (the core components of the RISC)
were expressed at lower levels in rapidly progressive IPF biopsies
and/or fibroblasts grown from the same biopsies compared with
both normal and slowly progressive IPF biopsies and fibroblasts.
Together, these data suggest that the development of IPF and/or
the pace of its clinical progression might be a consequence of
abnormal miRNA generation and processing.
Methods
Patients
All surgical lung biopsies (SLBs) were obtained from the patient
at the time of diagnosis of IPF. Patients were diagnosed with IPF
using a multidisciplinary approach involving a clinicians, radiol-
ogists, and pathologists [43]. A University of Michigan Institu-
tional Review Board approved this study and written informed
consent was obtained from each patient. IPF patients were
retrospectively grouped into a rapidly progressive group (n=9; 2
female and 7 male; median age 66) based on the following criteria
during the first year of follow-up: mortality or acute exacerbation,
percent forced vital lung capacity (FVC) decrease of $10%, and
percent diffusing capacity of carbon monoxide (DLCO) decrease of
$15%. IPF patients that did not meet these criteria over the first
year of follow-up were clinically diagnosed as slowly progressive
(n=6; 4 female and 2 male; median age=61 years). Samples
taken from disease-free patient autopsies were used as normal
controls (n=10; 5 female and 5 male; median age=24 years). A
University of British Columbia Institutional Review Board
approved the procurement and analysis of these tissues.
Total RNA and miRNA Isolation, and cDNA Generation
Left side upper and/or lower lobe surgical lung biopsies were
stored at 280uC and thawed on ice immediately prior to RNA
isolation. Approximately 1 ml of Trizol (Invitrogen Life Technol-
ogies, Carlsbad, CA) was added to each biopsy. Each biopsy was
homogenized using the Tissue-Tearor (Biospec Products, Bartles-
ville,OK)andtotalRNAextractionwasperformedaccording tothe
manufacturer’s instructions. Concentration and purity of each lung
sample was determined using a NanoDrop 1000 UV-Vis photo-
spectrometer (Thermo Scientific, Wilmington, DE). 1 mg of total
RNA from each biopsy was converted into cDNA using Murine
Moloney Leukemia Virus Reverse Transcriptase (Invitrogen Life
Technologies, Carlsbad, CA). MiRNA was isolated and purified
from 10 mg of total RNA according to manufacturer’s instruction
for the RT
2 qPCR-Grade miRNA Isolation Kit (SA Biosciences,
Frederick, MD). Concentration and purity were again measured
after miRNA isolation using the NanoDrop 1000 photospectrom-
eter and samples were screened for an A260:A280 ratio greater than
1.8. Conversion of miRNA to cDNA was carried out using 100 ng
of miRNA according to manufacturer’s instructions for the RT
2
miRNA First Strand Kit (SA Biosciences, Frederick, MD).
MicroRNA Array Analysis
MicroRNA expression values for each sample were measured
using a RT
2 miRNA PCR Array Human miFinder (SA
Biosciences, Frederick, MD). Plates contained 88 of the most
abundantly expressed and best-characterized miRNAs found in
humans as well as relevant housekeeping miRNA. Samples were
analyzed by quantitative real time polymerase chain reaction
(qRT-PCR) using the ABI 7500 Real Time PCR System (Applied
Biosystems, Foster City, CA) following the manufacturer’s
protocol. A dissociation curve was run to factor out wells with
nonspecific amplification and primer dimers. Samples were
grouped as normal, slowly progressive, and rapidly progressive
and analyzed using the PCR Array Data Analysis Excel Template
with the DDCt method (SA Biosciences, Frederick, MD). Data
were normalized using the small nuclear RNA housekeeping
panel: SNORD 47, SNORD 44, and U6.
Messenger RNA Target List Generation
MiRecords (http://mirecords.biolead.org/) [44] was used to
compile a list of experimentally validated miRNA targets. This is a
MicroRNA and Lung Fibrosis
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tal support.
Quantitative mRNA Analysis
Circular DNA (cDNA) made from total RNA was analyzed using
quantitative real time polymerase chain reaction (qRT-PCR) using
the ViiA 7 Real-Time PCR System (Applied Biosystems, Foster
City, CA). Pre-mixed primers and probes were purchased from
Applied Biosystems and used to detect human DICER1, AGO1, and
AGO2usinga 96wellformat.48genesassociatedwiththeepithelial-
mesenchymal transition (EMT) were analyzed using a preloaded
custom TaqMan Array Microfluidic Card (Applied Biosystems,
Foster City, CA). Data were normalized to an internal standard,
GAPDH in the 96 well format and to 18s in the card. Samples were
grouped into either slowly progressive IPF or rapidly progressive
IPF, and compared with normal using the DDCt method.
Immunohistochemistry
Five-micron thick paraffin-embedded tissue sections werecut from
formalin-fixed normal, slowly progressive, and rapidly progressive
SLBs. Each tissue sections was de-parafinized and rehydrated by
washing with xylene and a decreasing ethanol gradient. Sections
wereheated in10 mMcitricacid(pH 6.0)for12 minutesforantigen
retrieval and incubated for 30 minutes in a 10% methanol/ .4%
H2O2 solution to permeablize tissue sections and block endogenous
peroxidaseactivity.Tissue sectionswere additionallyblockedforwith
5% BSA/ 1% rabbit serum, Avidin Block (R and D Systems,
Minneapolis,MN),andBiotinBlock(RandDSystems,Minneapolis,
MN). The sections were incubated overnight at 4uCi na n t i - A G O 1
rabbit polyclonal antibody (4 or 20 mg/ml; BioLegend, San Diego,
CA) or anti-AGO2 rabbit polyclonal antibody (4 or 20 mg/ml;
,Abcam, Cambridge, MA). In-house non-specific rabbit polyclonal
IgG was used as a concentration matched negative control. Sections
were incubated with biotinylated anti-rabbit secondary antibody
(R&D Systems, Minneapolis, MN) for 1 hour then with HSS-HRP
Streptavidin Peroxidase (R&D Systems, Minneapolis, MN) for
30 minutes. Tissue was stained with DAB chromogen, counter-
stained with hematoxylin, and photographed with an Olympus
BX40 microscope and IP Lab Spectrum software (Signal Analytics
Corp, Vienna, VA).
Primary Pulmonary Fibroblast Culture and Treatment
To culture primary human fibroblasts, histologically normal
and IPF SLBs were finely minced and the dispersed tissue pieces
were placed into 150 cm
2 cell culture flasks with media. The
media consisted of DMEM (Lonza, Walkersville, MD) with 15%
fetal bovine serum (Cell Generation, Fort Collins, CO), 2 mmol/L
glutamine, and 16 Penicillin-Streptomycin-Amphotericin B
(Lonza, Walkersville, MD). Cells lines were cultured in media at
37uC in a 7% CO2 incubator and were serially passaged 4 times to
yield pure populations of adherent fibroblasts. All primary
fibroblast cell lines from each patient group were used between
passages 6 and 11. Prior to an experiment, fibroblasts from each
group (n=4 normal primary lines, n=6 stable primary IPF lines,
n=4 rapid primary IPF lines) were plated into a six-well tissue
culture plate with 5610
5 cells per well and activated for 4 hours
with media alone. Trizol reagent was added to each well to
terminate the experiment and mRNA was isolated and analyzed as
described above.
Statistical Analysis
Student’s T-test or Mann-Whitney test for non-normally
distributed data were used to determine statistical differences
Table 1. List of increased and decreased miRNA in rapidly
progressive IPF biopsies n=9) when compared to normal
lung samples (n=10) with p#0.05.
miRNA p-value Fold increase/decrease
miR-423-5p 0.0003 14.08
miR-155 0.0005 12.02
miR-128 0.0007 8.92
miR-374b 0.0062 7.87
miR-21 0.0325 6.75
miR-100 0.0052 6.40
miR-125b 0.0023 5.23
miR-140-3p 0.0047 3.97
miR-125a-5p 0.0330 3.94
miR-92a 0.0392 3.23
let-7c 0.0181 3.03
miR-181b 0.0379 22.13
let-7d 0.0225 22.42
miR-30c 0.0340 22.80
miR-27b 0.0392 23.16
miR-103 0.0055 23.33
miR-30a 0.0305 23.43
miR-424 0.0223 23.91
miR-22 0.0091 23.95
miR-186, miR-29a 0.0014 24.22
miR-126 0.0115 24.71
miR-27a 0.0215 25.33
miR-20a 0.0094 26.56
miR-143 0.0009 26.69
miR-223 0.0021 26.93
miR-17 0.0043 27.46
miR-106b 0.0002 27.52
miR-96 0.0111 27.96
miR-140-5p 0.0033 28.05
miR-15a 0.0003 28.32
miR-30b 0.0003 29.73
miR-130a 0.0003 29.92
miR-222, miR-30e 0.0004 210.54
miR-29c 0.00003 211.87
miR-18a 0.0001 214.58
miR-29b 0.0002 215.81
miR-142-5p 0.0014 217.92
miR-144 0.0202 220.07
miR-423-3p 0.0024 222.50
miR-142-3p 0.0003 227.70
miR-19b 0.0001 228.47
miR-19a 0.00003 232.63
miR-32 0.0012 235.70
miR-101 0.000001 245.83
miR-141 0.00001 2136.81
doi:10.1371/journal.pone.0021253.t001
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PRISM 5.0 software for Macintosh (GraphPad Software, San
Diego, CA). P#0.05 was considered statistically significant. The
statistical analysis performed on the EMT-associated genes used
qRT-PCR generated dCT values following the (Ct of gene of
interest (GOI) – Ct of housekeeping gene (HKG)) calculation.
Data were clustered using the absolute value of correlation
coefficients (distance measure) using hierarchical clustering to
show the genes that are strongly related in each group (Normal,
Slow, and Rapid) (R version 2.13.0, www.R-project.org). The
‘‘Ward’’ method, which derives spherical clusters has been used as
the agglomeration algorithm for forming clusters.
Results
Differential miRNA expression in whole lung samples
distinguished normal from IPF and rapidly from slowly
progressing IPF
Previous studies have identified global alterations in mRNA
transcript expression in IPF in terms of progression [14,15] and in
IPF with acute exacerbation [45]. To test the hypothesis that
altered mRNA transcript levels in IPF might be a consequence of
defective regulatory mechanisms, we investigated whether differ-
ences in miRNA expression might explain alterations in mRNA
expression in this disease. Using a quantitative real time miRNA
PCR array containing 88 of the most abundant miRNA found in
the human genome to analyze small RNA isolated from SLBs, a
number of significant differences in miRNA expression levels were
found in rapidly progressing IPF lung samples compared with
normal samples (Table 1). Of the 88 mature miRNA analyzed, 11
Table 2. List of increased and decreased miRNA in slowly
progressive IPF biopsies (n=6) when compared to normal
lung samples (n=10) with p#0.05.
miRNA p-value Fold increase/decrease
miR-155 0.02908 194.12
miR-128 0.01864 7.53
miR-125b 0.01713 5.33
miR-200c 0.02529 4.37
miR-181b 0.03575 22.82
miR-210 0.01265 23.31
miR-93 0.04296 23.55
miR-376c 0.03582 24.14
miR-126 0.03503 24.77
let-7d 0.00081 24.96
miR-29a 0.01268 25.09
miR-186 0.01107 25.14
miR-103 0.00474 25.24
miR-424 0.02294 25.56
miR-222 0.00053 25.59
miR-223 0.03748 25.92
miR-302c 0.04262 26.82
miR-22 0.00365 27.56
miR-20a 0.02531 27.65
miR-17 0.01641 27.98
miR-140-5p 0.01032 28.68
miR-15a 0.00501 28.81
miR-30e 0.01942 29.08
miR-29b 0.00691 210.02
miR-30b 0.00292 210.55
miR-29c 0.00086 211.30
miR-143 0.00061 211.61
miR-106b 0.00049 213.06
miR-18a 0.00081 222.35
miR-142-3p 0.00172 226.69
miR-142-5p 0.00220 228.06
miR-19b 0.00131 228.78
miR-130a 0.00001 229.93
miR-101 0.00072 234.27
miR-19a 0.00100 235.17
miR-32 0.00358 240.74
miR-144 0.01039 281.52
miR-141 0.00003 2220.92
doi:10.1371/journal.pone.0021253.t002
Figure 1. DICER1 expression does not differ between normal
and IPF biopsies. Total RNA from SLBs was analyzed by qRT-PCR for
transcript expression. Relative expression values were normalized to the
normal group (n=10) and compared to the slowly progressive (n=6) or
rapidly progressive group (n=9). Expression values were also normal-
ized to GAPDH. Data are presented as mean 6 SE.
doi:10.1371/journal.pone.0021253.g001
Table 3. List of increased and decreased miRNA in rapidly
progressive IPF biopsies (n=9) when compared with slow
progressive IPF biopsies (n=6) with p#0.05.
miRNA p-value Fold increase/decrease
miR-302c 0.0057 10.56
miR-423-5p 0.0191 7.97
miR-210 0.0212 4.50
miR-376c 0.0264 3.84
miR-185 0.0262 2.94
miR-423-3p 0.0128 297.68
doi:10.1371/journal.pone.0021253.t003
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miRNA were significantly decreased compared with the normal
lung samples. A comparison between slowly progressive IPF lung
biopsies and normal lung biopsies revealed that 4 miRNA were
significantly increased and 34 miRNA were significantly decreased
(Table 2). Lastly, a comparison between slowly and rapidly
progressive IPF biopsies revealed that 5 miRNA were significantly
increased and 1 miRNA was significantly decreased in rapid IPF
biopsies when compared to miRNA levels in slowly progressive
biopsies (Table 3). Overall, these data highlight that miRNA
levels in biopsies from rapidly and slowly progressive IPF exhibited
marked differences from normal lung biopsies; most of the miRNA
analyzed were significantly lower in IPF samples compared with
normal samples. However, miRNA expression in surgical lung
biopsy samples was different between rapidly and slowly
progressing IPF biopsies suggesting that an analysis of miRNA
biosynthesis and processing might reveal clues regarding the
differing rates of progression in pulmonary fibrosis.
Dicer1 transcript expression did not differ between
normal and IPF biopsies
Dicer1 is the ribonuclease required for the generation of mature
miRNAs from pre-miRNAs [23]. Given that the majority of
miRNA detected in both groups of IPF biopsies where significantly
lower when compared to the normal biopsies, we speculated that
altered DICER1 expression might account for these findings. Total
RNA from normal, slow IPF and rapid IPF biopsies was analyzed
for DICER1 expression using a qRT-PCR assay. DICER1 transcript
expression in the rapidly progressive IPF biopsies was only modestly
increased over the average levels of this transcript in both slowly
progressive IPF and normal biopsies (Figure 1). Thus, these
findings did not support our hypothesis that alterations in DICER1
expression might account for the differing miRNA generation in the
IPF lung biopsies compared with normal lung biopsies.
Numerous transcripts relevant to Epithelial-to-
Mesenchymal Transition (EMT) were validated targets of
the IPF miRNA profile
We next hypothesized that a decrease in miRNA expression
might explain, in part, the increased expression of fibrosis-related
mRNA transcripts observed in IPF biopsies compared with
normal or non-fibrotic lung biopsies. Unfortunately, predicting
miRNA gene targets is challenging because each target prediction
method predicts thousands of mRNA transcripts per miRNA.
Since each target prediction program’s methodology differs, these
programs also predict discordant mRNA transcripts for a given
miRNA. To lessen the discordance in miRNA target prediction,
we focused on compiling only experimentally validated miRNA
targets after an analysis of interactions. A list of experimentally
validated targets was compiled using the miRNA that differed
between slowly progressive and rapidly progressive IPF biopsies
compared to normal biopsies (Supporting Table S1). These
data revealed that many transcripts relevant to fibrosis are
validated targets of the miRNA present in the normal and IPF
biopsy samples including many EMT-related genes (Supporting
Table S1).
To explore the relevance of EMT in IPF progression, a
hierarchical clustering technique was used to determine the
dynamics of gene correlation changes between normal and IPF,
as well as between slow and rapid (Figure 2). Changes in the
dynamics of gene correlation were more pronounced between the
normal and rapid IPF groups and less pronounced between
normal and slow IPF groups (Figure 2). Assessment of the
clustering of specific EMT-related genes led to the observation
that GSK3b, COL3A1, SPARC and COL1A1 all correlated with
CD44 and VIM in normal lung biopsies, but not in rapid IPF lung
biopsy samples or in slow IPF lung tissue (Figure 2). This
suggested that the regulation of EMT-related genes was
diminished or absent in IPF compared with normal biopsies.
We next determined whether EMT-related genes differed in the
three groups of lung biopsies using TaqMan Array Microfluidic
Cards, and these data are summarized in Figure 3. CD44 and
COL1A2 mRNA levels were increased significantly in both slowly
progressive and rapidly progressive IPF biopsies compared to
normal biopsies (Figure 3 A–B). Messenger RNA levels of vimentin
were significantly increased in rapidly progressive IPF biopsies
compared with normal biopsies (Figure 3C). FOXC1 transcripts
did not differ among the three groups of biopsies (Figure 3D)
while FOXC2 expression was significantly higher in rapidly
progressive IPF and normal biopsies compared with biopsies from
Figure 2. Correlations are shown between EMT-related genes in normal, slow IPF, and rapid IPF lung biopsies. The dCT values were
clustered using the absolute value of correlation coefficients (distance measure) using hierarchical clustering to show the genes that are strongly
related at each stage (NORMAL, SLOW and RAPID). Lighter colors represent greater correlation between genes. The larger the value indicated, the
stronger the correlation. Negative values indicate a negative correlation.
doi:10.1371/journal.pone.0021253.g002
MicroRNA and Lung Fibrosis
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21253MicroRNA and Lung Fibrosis
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21253slowly progressive IPF patients (Figure 3E). FSCN1 (fascin
homolog 1, actin bundling protein) mRNA levels were significantly
decreased in slowly progressive biopsies and rapidly progressive
biopsies in comparison to normal tissue (Figure 3F). Together,
this quantitative PCR analysis suggested that although miRNA
species targeting EMT-related mesenchymal markers were
decreased in both groups of IPF patients, higher expression of
certain of these EMT-associated markers (including CD44,
COL1A2, VIM, and FOXC1) was apparent in rapid IPF versus
slow IPF.
MicroRNAs in lung biopsy samples differentiate rapid
from slow IPF. Further statistical analysis of miRNA expression
in biopsies from both groups of IPF patients revealed that 5
miRNAs were increased in rapid IPF versus slow IPF, and one
miRNA was decreased in rapid IPF versus slow IPF. A summary
of these miRNA and their validated targets is shown in Table 4.
Interestingly, few of these targets have been described in IPF aside
from HMGA2 [39], and none of the currently validated targets for
these miRNA appear to be directly involved in EMT.
Altered AGO1 and AGO2 transcript and AGO2 protein
levels in rapid IPF biopsies
Analysis of the increased miRNA species in the IPF biopsies
revealed that one of these miRNA (miR-128) targeted AGO1,
which is a core component of the RNA induced silencing complex
(RISC) [25,26] (Supporting Table S1). Argonaute proteins
function to bind the miRNA and correctly position it to recognize
the appropriate mRNA targets [46]. Consequently, the expression
levels of both AGO1 and AGO2 were analyzed at the transcript and
protein level in IPF and normal biopsies. Compared to normal
biopsies, AGO1 transcript levels in slow and rapid IPF biopsies
were significantly lower compared with levels in normal biopsies
(Figure 4A). In contrast, AGO2 levels were significantly higher in
rapid IPF biopsies compared with normal lung biopsies
(Figure 4B). Together, these data suggested that AGO1 and
AGO2 were differentially expressed in IPF compared with normal
biopsies.
To explore these transcript obervations further at the protein
level, immunohistochemical analysis was completed for AGO1
Table 4. List of experimentally validated miRNA gene targets
using miRecords, which are increased or decreased in rapid
IPF biopsies compared with slow IPF biopsies.
MiRNA Symbol Name
miR-302c ESR1 estrogen receptor 1
miR-423-5p none
miR-210 EFNA3 Ephrin-A3
MNT MAX binding protein
CASP8AP2 caspase-8-associated protein 2
miR-376c none
miR-185 CDK6 cyclin-dependent kinase 6
HMGA2 high mobility group AT-hook 2
AKT1 lv-akt murine thymoma viral oncogene
homolog 1
CCNE1 cyclin E1
CORO2B coronin, actin binding protein, 2B
miR-423-3p none
doi:10.1371/journal.pone.0021253.t004
Figure 4. Argonaute 1 (A) and Argonaute 2 (B) expression in
normal and IPF patient lung biopsies. Total RNA from SLBs was
analyzed by qRT-PCR for transcript expression. Relative expression
values were normalized to the normal group (n=10) and compared to
the slowly progressive (n=6) or rapidly progressive group (n=9).
Expression values were also normalized to GAPDH. Data are presented
as mean 6 SE. Significant differences are shown as *P#0.05.
doi:10.1371/journal.pone.0021253.g004
Figure 3. Differentially expressed transcripts of A) CD44,B )COL1A2,C )VIM,D )FOXC1,E )FOXC2, and F) FSCN1 in rapidly progressive
IPF and slowly progressive lung biopsies versus normal biopsies. Total RNA from SLBs was analyzed by qRT-PCR for transcript expression.
Relative expression values were normalized to the normal group (n=10) and compared to the slowly progressive (n=6) or rapidly progressive group
(n=9). Expression values were also normalized to GAPDH. Data are presented as mean 6 SE. Significant differences are shown as *P#.05 and
***P#.001.
doi:10.1371/journal.pone.0021253.g003
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revealed very little regardless of the antibody dilution or biopsy
group, perhaps due to the lack of a suitable antibody for formalin-
fixed tissues. However, AGO2 was detected in both slowly
progressive and rapidly progressive sections when this antibody
was used at a dilution of 20 mg/ml (Figure 5 A–D). However,
upon lowering the anti-AGO2 antibody concentration (i.e. to
4 mg/ml), AGO2 protein expression was present in the same
biopsies from both slowly progressive IPF and normal lung
sections, but staining for this protein at this antibody dilution was
absent in rapidly progressive biopsy sections (Figure 5 E–J).
Semi-quantitative results from this immunohistochemical analysis
are summarized in Table 5.
Decreased AGO1 transcript levels in rapid IPF biopsy-
derived fibroblasts compared with normal biopsy-
derived fibroblasts
DICER1, AGO1, and AGO2 expression were determined using
quantitative PCR in cultured primary pulmonary fibroblasts
grown from normal, slowly progressive IPF, or rapidly progressive
IPF patient biopsies. These cells were treated with media alone
and transcript levels were measured 4 h later. Median DICER1
transcript levels were higher in the slowly progressive IPF
fibroblast group compared with the other two groups
(Figure 6A). AGO1 expression was similar in the normal and
slowly progressive groups but 50% reduction in the levels of this
transcript were detected in cultures of fibroblasts from the rapidly
progressive IPF group compared with the normal fibroblast lines
(Figure 6B). Transcript levels of AGO2 followed the same pattern
of expression observed for DICER1; the highest levels of this
transcript were detected in fibroblasts from the slowly progressive
IPF group (Figure 6C). Overall, these data suggest that miRNA
biosynthesis and RISC function might be altered in fibroblasts
particularly from the rapidly progressive IPF group because of
decreased expression of DICER1 and AGO1, a catalytically active
component of the machinery required for RISC function in
fibroblasts from this group.
Discussion
Microarray-based methodology has been previously used to
identify transcript differences between biopsies from IPF and other
fibrotic and/or non-fibrotic lung diseases [12,13]. More recent
attention has turned to genome-wide profiling of transcripts in
biopsies taken from patients who experienced an acute exacerba-
tion of IPF [45] or from those who exhibited varying progression
of disease [14,15]. While IPF progression has been defined in two
published studies by Boon et al [14] and Selman et al [15], our
definition of rapidly progressive IPF more closely matches that
provided by Boon and colleagues [14]. Accordingly, rapidly
progressive IPF was defined as those patients exhibiting a FVC
and DLCO decline of $10% and $15%, respectively, over the first
12 months after diagnosis. Our results demonstrate that
quantitative differences in miRNA and mRNA expression in
diagnostic surgical lung biopsies distinguish varying speeds of IPF
progression. The lower expression levels of the majority of miRNA
present in IPF biopsies compared with normal tissue closely
mirrored findings in a wide variety of tumors compared with
appropriate control tissues [47] [48]. Further, several EMT-
related genes were found to be elevated in IPF biopsies
(particularly those from rapidly progressive IPF patients) com-
pared with normal biopsies. A comparison between slowly and
rapidly progressive IPF biopsies revealed 5 miRNA that were
significantly increased in rapid biopsies and 1 decreased when
compared to slowly progressive biopsies. No differences in the
expression of Dicer1 among the biopsy or fibroblast lines were
noted thus negating changes in miRNA processing as an
explanation for the changes in miRNA levels between the groups.
However, upon further investigation of miRNA processing
components, we observed that AGO1 levels in biopsies and
fibroblast lines and AGO2 protein levels in biopsies were reduced
in rapidly progressive IPF compared with normal samples.
Together, these data suggest that IPF is characterized by the
altered expression of miRNA and the decreased expression of key
RISC components might explain the rapidly progressive form of
this disease.
Our findings are consistent with a number of recently published
studies directed at the characterization of miRNA expression and
function in pulmonary fibrosis. First, a recent study by Pandit et al
[39] examined miRNA levels in IPF, irrespective of progression,
and observed that let-7d, miR-26, and members of the miR-30
family were all decreased in IPF biopsies compared with normal
biopsies. They further demonstrated that TGF-b inhibited let-7d
expression thereby driving the epithelial-mesenchymal transition
(EMT; see below) and increased collagen deposition [39]. In the
present study, we observed that members of the miR-30 and let-7d
families were significantly decreased in both forms of IPF
compared with normal biopsies. Second, Liu et al [40] reported
that miR-21 was increased in the lungs of patients with IPF,
irrespective again of disease progression, and that knocking down
miR-21 attenuated fibrosis in a bleomycin-induced fibrotic model.
They additionally found that an increase in miR-21 targets an
Table 5. Summary of semi-quantitative assessment of
immunohistochemical staining for Argonaute2 (antibody
dilution of 4 mg/ml) in normal, slow, and rapid IPF biopsies.
Progression Patient Result of Staining
Normal 134 positive
Normal 142 positive
Slow 69 positive
Slow 76 positive
Slow 98 weak positive
Rapid 10 negative
Rapid 26 negative
Rapid 56 negative
Rapid 57 negative
Rapid 67 weak positive
doi:10.1371/journal.pone.0021253.t005
Figure 5. Immunohistochemical analysis of Argonaute2 (AGO2) in tissues sections from slowly progressive, rapidly progressive, or
normal biopsies. Representative images of slowly progressive (A–B, E–F), rapidly progressive (C–D, G–H), and normal (I–J) biopsies stained with
IgG control (A, C, E, G, & I) and anti-AGO2 antibody (B, D, F, H, & J) are shown. Images A, B, C, & D were stained with antibody concentrations of
20 mg/ml and images E, F, G, H, I, & J were stained with an antibody concentration of 4 mg/ml. Sections were counterstained with hematoxylin.
Protein expression stains brown in this procedure (original magnification: 6200).
doi:10.1371/journal.pone.0021253.g005
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and a fibrotic phenotype [40]. Interestingly, our results revealed
that miR-21 was significantly increased in rapidly progressive IPF
biopsies compared with normal biopsies. Third, Cushing et al [41]
used a bleomycin-induced fibrotic mouse model and found that
the expression of miR-29 family miRNA was reduced in fibrotic
lungs, which corresponded with an increase in collagens and
ECM-related genes like laminins and integrins. In our study, we
observed significant decreases in miR-29b and miR-29c in slowly
progressive and rapidly progressive IPF patients compared to
normal. Also concordant with this previous study, we detected an
increase in COL1A2 (a miR-29b and miR-29c target) in IPF
patients. Thus, the findings from the present study coincide with
other published findings regarding the differential expression of
miRNA in clinical and experimental fibrosis.
DICER1 enzymatic activity is necessary for miRNA biogenesis
and loss of DICER1 expression through gene silencing and
knockout approaches has been shown to cause aberrant or
decreased endothelial cell proliferation [49], hair follicle develop-
ment [50], T cell development [51], lung epithelium morphogen-
esis [52], and reproductive development [53]. Loss of function
mutations in DICER1 is also associated with familial pleuropul-
monary blastoma [54], and its reduced expression contributes to
lung tumorigenesis [55,56]. In the majority of these disorders, the
reduction of DICER1 caused overall reductions in mature miRNA
levels, which contributes to the loss of transcript regulation.
However, analysis of DICER1 expression revealed no differences in
the amounts of this transcript amongst the biopsies and fibroblast
lines analyzed, leading us to presently conclude that changes in the
expression of DICER1 do not appear to explain the differential
miRNA levels in IPF versus normal.
EMT is the transition of differentiated epithelial cells into motile
mesenchymal cells, and this process is prominent in both
experimental and clinical pulmonary fibrosis [57–59]. Previous
studies have shown that miRNA regulation is critical in EMT. For
example, members of the miR-200 family (miR-200a, miR-200b,
miR-200c, miR-141, and miR-429) and miR-205 are decreased
when cells undergo EMT [60]. This group of miRNAs target
ZEB1 and SIP1, which repress E-cadherin and promote
mesenchymal marker expression. As expected [14,15], many of
the elevated mRNA transcripts detected in the IPF biopsies we
analyzed herein have been implicated in EMT. Further,
transcripts such as CD44, COL1A2, VIM, and FOXC2 were
significantly increased in rapidly progressive IPF over normal and/
or slowly progressive IPF biopsies. CD44 is a membrane associated
cellular adhesion receptor that plays a role in remodeling the lung
[61] through its ability to co-localize and bind with other EMT-
related proteins [62]. COL1A2 has been previously described in
IPF [45], and this gene was significantly increased in both forms of
IPF, perhaps due to the decreased miR-29b and miR-29c in these
biopsies. Vimentin is a definitive marker for the meshchymal cells
derived from epithelium [63] and an experimentally validated
target of miR-17. However, miR-17 was significantly decreased in
both forms of IPF compared with normal biopsies while levels of
Figure 6. Transcript expression of A) DICER1,B )AGO1,&C )
AGO2 in normal, slow IPF, and rapid IPF patient fibroblasts.
Fibroblasts cultured from normal, slow IPF, and rapid IPF lung biopsies
were exposed to media alone. Total RNA from cells was analyzed by
qRT-PCR for transcript expression 4 hours after treatment. Relative
expression values were normalized to the normal group (n=4) and
compared to the slowly progressive (n=6) or rapidly progressive group
(n=3). Expression values were also normalized to GAPDH. Data are
presented as mean 6 SE.
doi:10.1371/journal.pone.0021253.g006
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These data suggested that levels of a particular miRNA might be
less important than the processing efficiency of a particular
miRNA. Together, these data highlight that transcripts associated
with EMT were significantly elevated in IPF, particularly the
rapidly progressive form of this disease. The impact of differential
miRNA expression on EMT during IPF progression is presently
not clear and requires further investigation.
Argonaute proteins bind miRNA and position it in a
conformation that promotes mRNA target recognition [46]. They
are essential in every functional RISC and AGO2 is the
catalytically active ‘‘slicer’’ that cleaves mRNA transcripts [26].
Expanding on the observation that differential miRNA expression
did not fully explain the regulation of EMT-related genes in IPF of
variable progression, we investigated the expression of AGO1 and
AGO2 in biopsies and fibroblasts derived from the same biopsies.
The present study suggested that there was both a defect in
transcript and protein expression of these RISC components both
in biopsies and in cultured primary fibroblasts. Thus, the
impairment of miRNA-mediated gene silencing in rapidly
progressive forms of IPF could perhaps contribute to disease
progression. Future studies will be directed at determining what
mechanisms regulate Argonaute expression in IPF and whether
RISC function can be restored during fibrosis.
In summary, our results demonstrate that miRNA profiling in
diagnostic surgical lung biopsies differentiates normal from IPF,
and rapidly progressive IPF from slowly progressive IPF. Further
analysis of miRNA levels in circulating cells as a means of
ascertaining IPF disease progression is certainly warranted given
the present findings. Alterations in circulating miRNAs have been
detected in other diseases such as cancer. Finally, our results
indicate that aberrations in the miRNA processing pathway might
be the cause of altered transcript expression leading to the fibrotic
phenotype in IPF and the differing speed of progression of this
disease.
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